NASDAQ : RNTX
Rein Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.7266 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 62.68M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 10.36M | 10.90M | 13.86M | 11.36M | 9.68M | 9.60M |
| Research & Development | 10.39M | 11.03M | 14.25M | 3.99M | 17.97M | 17.01M |
| Operating Expenses | 20.76M | 21.93M | 28.11M | 15.35M | 27.65M | 26.61M |
| Operating Income | -20.76M | -21.93M | -28.11M | -15.35M | -27.65M | -26.61M |
| Interest & Investment Income | 700.00K | 600.00K | ||||
| Other Non Operating Income (Expenses) | -1.02M | 48.00K | -15.00K | -92.00K | 318.00K | -12.00K |
| EBT Excluding Unusual Items | -21.77M | -21.88M | -27.43M | -14.84M | -27.33M | -26.62M |
| Merger & Restructuring Charges | -928.00K | |||||
| Gain (Loss) on Sale of Assets | 36.00K | 66.00K | ||||
| Asset Writedown | -28.70M | -28.70M | -37.00M | |||
| Other Unusual Items | 387.00K | |||||
| Pretax Income | -50.47M | -50.58M | -64.43M | -15.73M | -27.33M | -26.16M |
| Income Tax Expense | -712.00K | -712.00K | -1.54M | |||
| Net Income | -49.76M | -49.87M | -62.88M | -15.73M | -27.33M | -26.16M |
| Net Income to Common | -49.76M | -49.87M | -62.88M | -15.73M | -27.33M | -26.16M |
| Shares Outstanding (Basic) | 85.77M | 25.44M | 17.94M | 4.60M | 4.54M | 4.44M |
| Shares Outstanding (Diluted) | 85.77M | 25.44M | 17.94M | 4.60M | 4.54M | 4.44M |
| EPS (Basic) | -0.58 | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 |
| EPS (Diluted) | -0.58 | -1.96 | -3.51 | -3.42 | -6.02 | -5.89 |
| Free Cash Flow | -18.83M | -19.36M | -22.29M | -19.81M | -24.86M | -23.91M |
| Free Cash Flow Per Share | -0.22 | -0.76 | -1.24 | -4.31 | -5.48 | -5.38 |
| EBITDA | -20.76M | -21.93M | -28.05M | -15.23M | -27.48M | -26.48M |
| D&A For EBITDA | 500.00 | 1.00K | 63.00K | 119.00K | 169.00K | 121.00K |
| EBIT | -20.76M | -21.93M | -28.11M | -15.35M | -27.65M | -26.61M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.54M | 3.21M | 12.87M | 17.31M | 5.19M | 3.60M |
| Short-Term Investments | 32.10M | 16.05M | 42.33M | |||
| Cash & Short-Term Investments | 40.65M | 3.21M | 12.87M | 17.31M | 21.24M | 45.93M |
| Prepaid Expenses | 606.00K | 2.22M | ||||
| Restricted Cash | 25.00K | 25.00K | 25.00K | |||
| Other Current Assets | 806.00K | 1.11M | 792.00K | 928.00K | ||
| Total Current Assets | 41.45M | 4.33M | 13.66M | 18.27M | 21.87M | 48.18M |
| Property, Plant & Equipment | 1.00K | 19.00K | 110.00K | 280.00K | ||
| Goodwill | 6.33M | 6.33M | 6.33M | 6.33M | ||
| Other Intangible Assets | 13.50M | 13.50M | 42.20M | 79.20M | ||
| Long-Term Deferred Charges | 1.71M | 2.14M | ||||
| Other Long-Term Assets | 2.00K | 2.00K | 53.00K | 24.00K | 24.00K | |
| Total Assets | 65.97M | 24.16M | 62.19M | 106.01M | 22.01M | 48.48M |
| Accounts Payable | 4.47M | 3.98M | 911.00K | 1.19M | 1.72M | 1.21M |
| Accrued Expenses | 1.47M | 2.11M | 4.72M | 2.94M | 1.45M | 3.15M |
| Current Portion of Leases | 48.00K | 33.00K | 93.00K | |||
| Other Current Liabilities | 3.77M | 98.00K | 122.00K | 206.00K | 181.00K | 60.00K |
| Total Current Liabilities | 9.71M | 6.18M | 5.75M | 4.38M | 3.38M | 4.51M |
| Long-Term Leases | 69.00K | |||||
| Long-Term Deferred Tax Liabilities | 1.06M | 1.06M | 1.77M | 3.33M | ||
| Other Long-Term Liabilities | 277.00K | |||||
| Total Liabilities | 10.77M | 7.24M | 7.80M | 7.71M | 3.38M | 4.58M |
| Common Stock | 172.00K | 113.00K | 108.00K | 91.00K | 91.00K | 91.00K |
| Additional Paid-In Capital | 423.58M | 373.13M | 360.70M | 295.38M | 291.37M | 289.28M |
| Retained Earnings | -413.48M | -401.27M | -351.40M | -288.52M | -272.79M | -245.46M |
| Comprehensive Income & Other | -69.00K | -62.00K | -18.00K | -63.00K | -48.00K | -13.00K |
| Total Common Equity | 10.20M | -28.09M | 9.39M | 6.89M | 18.62M | 43.90M |
| Shareholders' Equity | 55.20M | 16.92M | 54.39M | 98.30M | 18.62M | 43.90M |
| Total Liabilities & Equity | 65.97M | 24.16M | 62.19M | 106.01M | 22.01M | 48.48M |
| Total Debt | 48.00K | 33.00K | 162.00K | |||
| Net Cash (Debt) | 40.65M | 3.21M | 12.87M | 17.27M | 21.21M | 45.77M |
| Net Cash Per Share | 0.47 | 0.13 | 0.72 | 3.75 | 4.67 | 10.31 |
| Filing Date Shares Outstanding | 86.27M | 28.04M | 21.99M | 16.97M | 4.54M | 4.53M |
| Total Common Shares Outstanding | 85.77M | 27.55M | 21.67M | 4.89M | 4.54M | 4.53M |
| Working Capital | 31.74M | -1.85M | 7.91M | 13.88M | 18.49M | 43.67M |
| Book Value Per Share | 0.12 | -1.02 | 0.43 | 1.41 | 4.10 | 9.69 |
| Tangible Book Value | -9.63M | -47.92M | -39.14M | -78.64M | 18.62M | 43.90M |
| Tangible Book Value Per Share | -0.11 | -1.74 | -1.81 | -16.10 | 4.10 | 9.69 |
| Machinery | 340.00K | 340.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -49.76M | -49.87M | -62.88M | -15.73M | -27.33M | -26.16M |
| Depreciation & Amortization | 1.00K | 63.00K | 119.00K | 169.00K | 121.00K | |
| Other Amortization | 1.07M | |||||
| Loss (Gain) From Sale of Assets | -36.00K | -66.00K | ||||
| Asset Writedown & Restructuring Costs | 28.70M | 28.70M | 37.00M | |||
| Loss (Gain) From Sale of Investments | 32.00K | -208.00K | 240.00K | |||
| Stock-Based Compensation | 2.02M | 2.22M | 1.12M | 1.19M | 2.08M | 2.26M |
| Other Operating Activities | 869.00K | 450.00K | -387.00K | |||
| Change in Accounts Payable | -1.65M | 3.06M | -279.00K | -4.98M | 510.00K | -386.00K |
| Change in Other Net Operating Assets | 625.00K | -3.22M | 4.25M | -399.00K | -90.00K | 628.00K |
| Operating Cash Flow | -18.83M | -19.36M | -22.29M | -19.81M | -24.86M | -23.75M |
| Capital Expenditures | -157.00K | |||||
| Sale of Property, Plant & Equipment | 42.00K | 66.00K | ||||
| Cash Acquisitions | -96.00K | |||||
| Investment in Securities | -35.07M | 16.25M | 26.46M | -35.83M | ||
| Investing Cash Flow | -35.07M | 16.20M | 26.46M | -35.92M | ||
| Long-Term Debt Issued | 15.79M | |||||
| Net Debt Issued (Repaid) | -1.07M | 15.79M | ||||
| Issuance of Common Stock | 55.00M | 3.44M | 10.79M | 59.16M | ||
| Other Financing Activities | 2.85M | 6.32M | 7.03M | -3.51M | ||
| Financing Cash Flow | 56.77M | 9.76M | 17.82M | 15.79M | 55.66M | |
| Foreign Exchange Rate Adjustments | -49.00K | -44.00K | -63.00K | |||
| Net Cash Flow | 2.82M | -9.65M | -4.47M | 12.12M | 1.59M | -4.01M |
| Free Cash Flow | -18.83M | -19.36M | -22.29M | -19.81M | -24.86M | -23.91M |
| Free Cash Flow Per Share | -0.22 | -0.76 | -1.24 | -4.31 | -5.48 | -5.38 |
| Levered Free Cash Flow | -7.79M | -11.37M | -14.82M | -7.62M | -14.48M | -13.50M |
| Unlevered Free Cash Flow | -8.86M | -11.37M | -14.82M | -7.62M | -14.48M | -13.50M |
| Change in Working Capital | -1.74M | -865.00K | 2.41M | -5.38M | 420.00K | 242.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 57.80M | 30.49M | 49.83M | 14.89M | 10.76M | 50.98M |
| Enterprise Value | 17.15M | 71.45M | 77.18M | 2.83M | -14.65M | -1.06M |
| Last Close Price | 0.67 | 1.16 | 2.30 | 3.05 | 2.37 | 11.26 |
| PB Ratio | 5.63 | 1.80 | 0.92 | 0.15 | 0.58 | 1.16 |
| P/TBV Ratio | 0.58 | 1.16 | ||||
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | |||
| Net Debt / Equity Ratio | -0.74 | -0.19 | -0.24 | -0.18 | -1.14 | -1.04 |
| Net Debt / EBITDA Ratio | 1.96 | 0.15 | 0.46 | 1.13 | 0.77 | 1.73 |
| Net Debt / FCF Ratio | 2.16 | 0.17 | 0.58 | 0.87 | 0.85 | 1.91 |
| Quick Ratio | 4.19 | 0.52 | 2.24 | 3.95 | 6.28 | 10.19 |
| Current Ratio | 4.27 | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 |
| Return on Equity (ROE) | -96.42% | -139.87% | -82.37% | -26.91% | -87.41% | -93.33% |
| Return on Assets (ROA) | -21.02% | -31.75% | -20.89% | -14.99% | -49.03% | -51.30% |
| Return on Capital Employed (ROCE) | -36.90% | -122.00% | -49.80% | -15.10% | -148.50% | -60.50% |
| Earnings Yield | -86.60% | -163.55% | -126.19% | -105.62% | -253.93% | -51.32% |
| FCF Yield | -32.58% | -63.50% | -44.73% | -132.99% | -231.03% | -46.90% |
| Buyback Yield / Dilution | -283.20% | -41.84% | -290.09% | -1.31% | -2.23% | -154.70% |